Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CVRXNASDAQ:DXRNYSE:ELMDNASDAQ:RCEL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCVRXCVRx$5.96+2.1%$6.49$4.30▼$18.55$153.62M1.3320,636 shs30,370 shsDXRDaxor$9.25+2.8%$8.02$6.55▼$10.00$44.77M-0.135,767 shs3,659 shsELMDElectromed$20.56-0.9%$21.47$13.74▼$35.56$172.67M0.473,253 shs5,589 shsRCELAvita Medical$5.23-0.4%$7.44$5.10▼$14.16$137.57M1.55182,936 shs49,146 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCVRXCVRx0.00%-1.69%-16.60%-53.32%-47.24%DXRDaxor0.00%+2.39%+18.42%+8.04%+1.93%ELMDElectromed0.00%+3.65%-6.66%-16.13%+46.57%RCELAvita Medical0.00%-9.48%-21.64%-41.41%-34.54%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCVRXCVRx2.2946 of 5 stars3.42.00.00.00.04.20.6DXRDaxorN/AN/AN/AN/AN/AN/AN/AN/AELMDElectromed1.1575 of 5 stars2.05.00.00.00.61.70.0RCELAvita Medical1.3359 of 5 stars3.40.00.00.02.70.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCVRXCVRx 2.71Moderate Buy$14.50143.49% UpsideDXRDaxor 3.00Buy$25.00170.27% UpsideELMDElectromed 4.00Strong Buy$38.0084.84% UpsideRCELAvita Medical 2.75Moderate Buy$16.50215.49% UpsideCurrent Analyst Ratings BreakdownLatest DXR, CVRX, ELMD, and RCEL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/6/2025RCELAvita MedicalD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$19.005/15/2025ELMDElectromedB. RileySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/9/2025CVRXCVRxPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$20.00 ➝ $12.005/9/2025CVRXCVRxJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Underweight$15.00 ➝ $7.004/10/2025RCELAvita MedicalD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.00 ➝ $22.004/8/2025CVRXCVRxLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$19.00 ➝ $14.004/8/2025CVRXCVRxCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$23.00 ➝ $18.004/4/2025RCELAvita MedicalD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.00 ➝ $22.00(Data available from 6/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCVRXCVRx$52.87M2.94N/AN/A$2.93 per share2.03DXRDaxorN/AN/AN/AN/AN/AN/AELMDElectromed$61.44M2.81$0.50 per share41.36$5.10 per share4.03RCELAvita Medical$64.25M2.15N/AN/A$0.17 per share30.76Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCVRXCVRx-$59.97M-$2.18N/AN/AN/A-97.49%-79.04%-42.37%8/4/2025 (Estimated)DXRDaxorN/AN/A0.00∞N/AN/AN/AN/AN/AELMDElectromed$5.15M$0.7927.45∞N/A11.34%15.71%13.37%N/ARCELAvita Medical-$61.85M-$2.19N/AN/AN/A-79.61%-632.62%-71.72%8/6/2025 (Estimated)Latest DXR, CVRX, ELMD, and RCEL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/8/2025Q1 2025CVRXCVRx-$0.56-$0.53+$0.03-$0.53$14.68 million$12.35 million5/8/2025Q1 2025RCELAvita Medical-$0.39-$0.53-$0.14-$0.53$33.15 million$18.51 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCVRXCVRxN/AN/AN/AN/AN/ADXRDaxorN/AN/AN/AN/AN/AELMDElectromedN/AN/AN/AN/AN/ARCELAvita MedicalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCVRXCVRx0.7114.8213.45DXRDaxorN/AN/AN/AELMDElectromedN/A5.104.74RCELAvita Medical9.392.091.72Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCVRXCVRx75.27%DXRDaxor1.34%ELMDElectromed40.82%RCELAvita Medical27.66%Insider OwnershipCompanyInsider OwnershipCVRXCVRx13.90%DXRDaxor59.50%ELMDElectromed14.00%RCELAvita Medical2.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCVRXCVRx16026.07 million22.45 millionOptionableDXRDaxor374.84 million1.96 millionNot OptionableELMDElectromed1608.39 million7.36 millionOptionableRCELAvita Medical13026.43 million25.70 millionOptionableDXR, CVRX, ELMD, and RCEL HeadlinesRecent News About These CompaniesReviewing Beyond Air (NASDAQ:XAIR) and AVITA Medical (NASDAQ:RCEL)June 15, 2025 | americanbankingnews.comCantor Fitzgerald Comments on AVITA Medical FY2026 EarningsJune 12, 2025 | americanbankingnews.comCantor Fitzgerald Predicts AVITA Medical FY2026 EarningsJune 11, 2025 | marketbeat.comAVITA Medical (NASDAQ:RCEL) Given Buy Rating at D. Boral CapitalJune 6, 2025 | marketbeat.comAVITA Medical Announces First Clinical Publication Demonstrating Accelerated Autograft Readiness with Cohealyx™June 5, 2025 | finance.yahoo.comAVITA Medical's RECELL Platform Recognized for Surgical Innovation in 2025 MedTech Breakthrough AwardsJune 3, 2025 | globenewswire.comShort Interest in AVITA Medical, Inc. (NASDAQ:RCEL) Rises By 23.9%June 3, 2025 | marketbeat.comDelta Investment Management LLC Increases Holdings in AVITA Medical, Inc. (NASDAQ:RCEL)May 22, 2025 | marketbeat.comAVITA Medical’s Acute Wound Care Showcase 2025 Streams Live TodayMay 13, 2025 | finance.yahoo.comAVITA Medical: Near-Perfect Execution Needed To Navigate Through Balance Sheet ChallengesMay 12, 2025 | seekingalpha.comAnalysts Have Been Trimming Their AVITA Medical, Inc. (NASDAQ:RCEL) Price Target After Its Latest ReportMay 11, 2025 | finance.yahoo.comAVITA Medical, Inc. (RCEL) Q1 2025 Earnings Call TranscriptMay 8, 2025 | seekingalpha.comAVITA Medical Reports First Quarter 2025 Financial ResultsMay 8, 2025 | globenewswire.comAVITA Medical to Announce First Quarter 2025 Financial ResultsApril 17, 2025 | globenewswire.comAVITA Medical to Present Breakthrough Clinical Data in Burn and Wound Care at ABA 2025April 9, 2025 | globenewswire.com6 Analysts Assess AVITA Medical: What You Need To KnowApril 6, 2025 | nasdaq.comAvita Medical announces U.S. commercial launch of CohealyxApril 4, 2025 | msn.comAVITA Medical Launches Cohealyx, Supporting Healing and Unlocking New Market OpportunityApril 3, 2025 | globenewswire.comAVITA Medical’s SWOT analysis: regenerative medicine stock faces growth hurdlesMarch 21, 2025 | uk.investing.com4RCEL : What Analysts Are Saying About AVITA Medical StockMarch 18, 2025 | benzinga.comAvita Medical amends PermeaDerm distribution agreement with Stedical ScientificMarch 17, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeDXR, CVRX, ELMD, and RCEL Company DescriptionsCVRx NASDAQ:CVRX$5.96 +0.13 (+2.14%) As of 10:17 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure. It sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, and internationally. The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.Daxor NASDAQ:DXR$9.25 +0.25 (+2.78%) As of 09:47 AM EasternDaxor Corporation, a medical device company, provides blood volume measurement technology focused on blood volume testing. The company develops and markets BVA-100 Blood Volume Analyzer, a diagnostic blood test to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms for used in a broad range of medical and surgical conditions. The company was formerly known as Idant Corporation and changed its name to Daxor Corporation in May 1973. Daxor Corporation was incorporated in 1971 and is headquartered in Oak Ridge, Tennessee. Daxor Corporation is a subsidiary of Estate Of Joseph Feldschuh.Electromed NYSE:ELMD$20.56 -0.18 (-0.88%) As of 10:17 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy and amyotrophic lateral sclerosis; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions. It also provides single patient use SmartVest and SmartVest Wrap products for health care providers in the acute care setting. The company offers its products to hospitals, home health care centers, pulmonary rehabilitation centers, cystic fibrosis centers, neuromuscular clinics, and other clinics through distributors. It markets its products to physicians, health care providers, and directly to patients. Electromed, Inc. was incorporated in 1992 and is headquartered in New Prague, Minnesota.Avita Medical NASDAQ:RCEL$5.23 -0.02 (-0.38%) As of 10:16 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Robinhood Director Sells Millions, But HOOD Stock Eyes Gains Coinbase Stock Pops as Senate Passes GENIUS Stablecoin Bill Chime’s Smart IPO: Half the Valuation, Double the Strength 3 Tech Stocks With High and Rising Institutional Interest Salesforce Raises Prices: 3 Reasons Its Stock Price Will Follow Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
